anonymous
Guest
anonymous
Guest
Folks whatever happened to the slew of new promising drug pipeline at GNE? It has been bone dry with recent injunction against Emicizumab (Chugai molecule). Two once promising molecules failed Ph III with badly needed Lampalizumab for the beaten and worse to come Retina franchise (slew of Avastin biosims soon) and once rising star asthma drug but dead Lebrikizumab sold for peanuts - $135 mil.
Folks - it all points to MAJOR layoffs in SSF lala land and field sales as it's lot harder and very expensive to let people go in Baseland. Swiss folks were not too thrilled with too many reps to begin with and let's face it - just drag to the margins anyway for living the country club lifestyle which was otay when gravy poured in but not when Rituxan/Herceptin/Avastin biosims are about to take monopoly market share. Basel tower honchos will engage McKinsey and say what bottom lines to sales and financial impact did old stodgy pharmas face when they decimated the reps, i.e., Pfizer.
Time to polish them CVs...
Folks - it all points to MAJOR layoffs in SSF lala land and field sales as it's lot harder and very expensive to let people go in Baseland. Swiss folks were not too thrilled with too many reps to begin with and let's face it - just drag to the margins anyway for living the country club lifestyle which was otay when gravy poured in but not when Rituxan/Herceptin/Avastin biosims are about to take monopoly market share. Basel tower honchos will engage McKinsey and say what bottom lines to sales and financial impact did old stodgy pharmas face when they decimated the reps, i.e., Pfizer.
Time to polish them CVs...